Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website


ALKERMES reported $-28780000 in EBITDA for its fiscal quarter ending in March of 2023.

Ebitda Change
Acadia Pharmaceuticals ACAD:US USD -53158000 7.58M
Amgen AMGN:US USD 3B 42M
Biogen BIIB:US USD 686.7M 312.1M
BioMarin Pharmaceutical BMRN:US USD 87.87M 87.82M
Bluebird Bio BLUE:US USD -83411000 8.1M
Bristol-Myers Squibb BMY:US USD 5.43B 772M
Eli Lilly LLY:US USD 1.96B 528.3M
Gilead Sciences GILD:US USD 2.24B 456M
Horizon Pharma HZNP:US USD 133.36M 180.38M
Intra Cellular Therapies ITCI:US USD -48258000 1.03M
Ionis Pharmaceuticals IONS:US USD -110937000 93.44M
J&J JNJ:US USD 9B 934.8M
Marinus Pharmaceuticals MRNS:US USD -32806000 3.68M
Minerva Neurosciences NERV:US USD -5341000 278K
Nektar Therapeutics NKTR:US USD -34714000 2.99M
Neurocrine Biosciences NBIX:US USD 34.7M 73.1M
Otsuka Holdings 4578:JP JPY 94.16B 25.42B
Pfizer PFE:US USD 8.01B 683M
Regeneron Pharmaceuticals REGN:US USD 1.1B 195.4M
Revance Therapeutics RVNC:US USD -51414000 5.74M
Vertex Pharmaceuticals VRTX:US USD 817.8M 254.1M